AACI

Meeting Program
Continuing Medical Education (CME) is jointly sponsored by the Vanderbilt School of Medicine and the Association of American Cancer Institutes.
Sunday, October 3
11:00 am	Meeting Registration Begins
12:45 pm	Welcome Program Committee Leadership Ms. Barbara Duffy Stewart Association of American Cancer Institutes Mr. Randy Main Fred Hutchinson Cancer Research Center Mr. Robert J. DuWors Jonsson Comprehensive Cancer Center, UCLA
1:00 pm	Informatics of Genomics – Implications for Cancer Center More sophisticated data management and analysis methods are needed to handle the growing volumes of information and data housed in AACI cancer centers. To address this challenge, cancer center representatives will explore a number of possible solutions, including strategic talent development, working with genome centers, and, accessing public databases and informatics resources. Presentations will be followed by a discussion of approaches to high throughput sequencing and issues of infrastructure costs, new technology, and competitive grants. Jim Mullikin (NHGRI), (Kevin P. White (confirmed - University of Chicago Moderator: Dr. Richard Wilson Washington University Genome Center Dr. Richard Gibbs (invited) Baylor College of Medicine Dr. Raynard S. Kington National Institutes of Health
2:30 pm	Break
2:45 pm	Creating Economies of Scale in Managing Multiple Research Infrastructure Awards With increased emphasis on team science and research centers at major academic institutions, this session will provide a forum for discussing vital issues associated with managing multiple research infrastructure awards, including: reconciling inconsistent federal guidelines and policies; managing shared resources that appear in multiple center grants and establishing consistent methods of determining costs. Moderator: Dr. Benz Dr. Barbara Alving National Center for Research Resources National Institutes of Health Dr. Barry S. Coller The Rockefeller University Ms. Lynda Jacobsen UCSF Helen Diller Family Comprehensive Cancer Center and Cancer Research Institute University of California San Francisco Ms. Jeanine Stiles UC Davis Cancer Center Dr. Linda Weiss Cancer Centers Branch National Cancer Institute
4:00 pm	Break
4:30 pm	CCAF Business Meeting
5:00 pm	Session ends
6:00 - 7:00 pm	Welcome Reception
Monday, October 19
General Session
7:00 am	Continental breakfast
7:00 am	Breakfast Roundtable Discussions
7:00 am	Exhibits Open
8:00 am	A Decade of Targeted Therapies: What Have We Learned? The challenges and rewards of targeted therapy development will be examined as viewed through specific case studies. The session will highlight the following issues: • How trials are designed; • How subjects are identified and enrolled; • How new tools (e.g., advanced imaging) are added to the protocol design; • Whether or not combination agents should be tested; • Additional costs associated with adding new tools; and • What investigators are learning that’s new information for clinical trialists. Moderator: Dr. Benz Dr. Pasi A. Jänne Harvard Medical School Dana-Farber Cancer Institute Dr. Frank McCormick UCSF Helen Diller Family Comprehensive Cancer Center UCSF Cancer Research Institute Dr. David R. Parkinson Nodality
9:30 am	Break
9:50 am	Maximizing Cancer Center Resources in a Challenging Economy Leaders from the represented cancer centers will describe strategies and provide perspective on how their centers are operating in the current volatile economy, using case studies for illustration. Discussion will focus on the economy’s impact and centers' evolving challenges associated with recruitment and retention, development, capital improvements, and bridge funding for under-funded investigators. Moderator: Mr. Theodore J. Yank The Dan L. Duncan Cancer Center at Baylor College of Medicine Dr. Van Cherington The Wistar Institute, Wistar Cancer Center Mr. Main Mr. Brian C. Springer The Alvin J. Siteman Cancer Center of Barnes-Jewish Hospital at Washington University School of Medicine Ms. Marcy B. Waldinger University of Michigan Comprehensive Cancer Center

11:20 am	AACI Clinical Research Initiative Update AACI has established the AACI Clinical Research Initiative (CRI) – a communications network for clinical research leaders across the AACI cancer center network to address barriers associated with the development of cancer therapies and enrollment of patients to cancer clinical trials at academic cancer centers. Dr. James Thomas The Ohio State University Comprehensive Cancer Center
12:00 pm	AACI Awards Luncheon
1:30 pm	2009 AACI Distinguished Scientist Award Dr. Janet D. Rowley will receive the 2009 Distinguished Scientist Award. The award recognizes Dr. Rowley’s leadership in the oncology and biomedical communities and her landmark research, particularly, her discoveries of chromosome abnormalities in human leukemia and lymphoma – including the identification of the first consistent chromosome translocation in any human cancer, the 9;22 translocation in chronic myelogenous leukemia – that has led to the development of today’s targeted therapies, such as Gleevec. Dr. Janet D. Rowley University of Chicago
2:30 pm	Cancer costs and medical progress: How much can we afford? While improved medical technology has led to great progress in managing cancer, it has also contributed to a steady rise in the costs of caring for cancer patients. Dr. Callahan will explore how these costs can be controlled, as well as the ethical arguments for and against limiting the use of medical technologies. Dr. Daniel Callahan The Hastings Center
3:30 pm	Break
3:45 pm	Managing Tissue Resources at Cancer Centers With the growing emphasis on translational research and “personalized medicine”, the need for high quality biospecimens is dramatically increasing. How tissue procurement is managed at cancer centers will have a dramatic impact on cancer research and patient care. Panelists will discuss universal direct consent, NIH guidelines for non-human subject research and state and federal laws related to use of tissues. Moderator: Dr. Carl D. Morrison Roswell Park Cancer Institute Dr. Carolyn Compton National Cancer Institute Dr. Scott D. Jewell The Ohio State University Comprehensive Cancer Center - James Cancer Hospital & Solove Research Institute Mr. Paul Papagni The University of Texas M.D. Anderson Cancer Center Ms. Camille Wicher Roswell Park Cancer Institute
5:15 pm	Session Ends
6:00 - 7:30 pm	President's Reception
Tuesday, October 20
7:00 am	Continental Breakfast
7:00 am	Breakfast Roundtable Discussions
7:00 am	Exhibits Open
General Session
8:00 am	NCI Grants Management Office An update of NCI grants-related policy and procedures and submission guidelines will be presented. Mr. Leo Buscher National Cancer Institute
9:00 am	Comparative Effectiveness Research: Potential Impact on the Quality of Cancer Care The National Institutes of Health defines Comparative Effective Research (CER) as a rigorous evaluation of different treatment options that are available for treating a given medical condition for a particular set of patients. Such a study may compare similar treatments, such as competing drugs, or it may analyze very different approaches, such as surgery and drug therapy. This session will provide an overview of CER’s potential impact on the quality of cancer care from a number of perspectives, including speakers from academia and the patient advocacy community. Moderator: Dr. Ellen V. Sigal Friends of Cancer Research Ms. Nancy Davenport-Ennis National Patient Advocate Foundation Dr. Elizabeth Lamont Dana-Farber Cancer Institute Dr. Gilbert Omenn University of Michigan
10:30 am	Break
10:45 am	Cancer 2.0: A Vision to Transform the U.S. Cancer Research Enterprise Dr. Richard Klausner The Column Group
11:45 pm	Adjourn
	Program Subject to Change

Continuing Medical Education Accreditation This activity has been planned and implemented in accordance with the Essentials Areas and Policies of the Accreditation Council for CME (ACCME) through the joint sponsorship of Vanderbilt School of Medicine and (the non-accredited joint sponsor). Vanderbilt School of Medicine is accredited by the Accreditation Council for CME to sponsor continuing medical education for physicians. Credit Designation Vanderbilt School of Medicine designates this educational activity for a maximum of 13.5 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity. Learning Objectives After participating in this CME activity, participants should be able to describe and discuss: • Potential new policies and strategies that may govern the policies of federal agencies overseeing the national cancer research enterprise, including NIH and NCI. • Challenges associated with new information about the development of applications for targeted therapies in cancer. • Methods to harmonize goals among centers and maximize cancer center resources in difficult economic conditions. • Strategies to increase the overall value of and access to quality cancer care in relationship to the patient, provider, and payor and other integral stakeholders. Americans with Disabilities Act It is the policy of Vanderbilt School of Medicine not to discriminate against any person on the basis of disabilities. If you feel you need services or auxiliary aids mentioned in this act in order to fully participate in this continuing education activity, please contact Sara Arvay at 412-605-1476 or attach a note to your registration form. Faculty Disclosure It is the policy of Vanderbilt School of Medicine that participants in CME activities be made aware of any affiliation or financial interest that may affect the planner’s involvement and speaker’s presentation(s). Each course director, planner and speaker has completed and signed a conflict of interest statement. The faculty members’ relationships will be disclosed to the audience. Target Audience This conference is designed for basic and clinical scientists, as well as for physician-scientists from academia, industry, government, and other institutions with interest in diagnosing, preventing, and treating cancer and its long-term effects.